AP1917A - Azaindoles - Google Patents

Azaindoles

Info

Publication number
AP1917A
AP1917A AP2006003492A AP2006003492A AP1917A AP 1917 A AP1917 A AP 1917A AP 2006003492 A AP2006003492 A AP 2006003492A AP 2006003492 A AP2006003492 A AP 2006003492A AP 1917 A AP1917 A AP 1917A
Authority
AP
ARIPO
Prior art keywords
azaindoles
Prior art date
Application number
AP2006003492A
Other languages
English (en)
Other versions
AP2006003492A0 (en
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Chris Edlin
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of AP2006003492A0 publication Critical patent/AP2006003492A0/xx
Application granted granted Critical
Publication of AP1917A publication Critical patent/AP1917A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
AP2006003492A 1999-12-24 2000-12-27 Azaindoles AP1917A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (fr) 1999-12-24 2000-12-27 Azaindoles

Publications (2)

Publication Number Publication Date
AP2006003492A0 AP2006003492A0 (en) 2006-02-28
AP1917A true AP1917A (en) 2008-11-12

Family

ID=26316153

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.
AP2006003492A AP1917A (en) 1999-12-24 2000-12-27 Azaindoles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.

Country Status (27)

Country Link
US (2) US6770643B2 (fr)
EP (2) EP1990343B1 (fr)
JP (1) JP5436507B2 (fr)
KR (2) KR100910488B1 (fr)
CN (2) CN100379734C (fr)
AP (2) AP1587A (fr)
AU (1) AU777717B2 (fr)
BG (2) BG66066B1 (fr)
BR (1) BR0017038A (fr)
CA (2) CA2395593C (fr)
CY (1) CY1110951T1 (fr)
CZ (2) CZ301751B6 (fr)
DZ (1) DZ3377A1 (fr)
EA (1) EA005212B1 (fr)
EE (1) EE05180B1 (fr)
HK (1) HK1050191B (fr)
HR (1) HRP20020547B1 (fr)
HU (1) HUP0203895A3 (fr)
IL (3) IL150388A0 (fr)
MA (1) MA26857A1 (fr)
MX (1) MXPA02006338A (fr)
NO (2) NO323766B1 (fr)
NZ (1) NZ519121A (fr)
OA (1) OA12514A (fr)
PL (1) PL209572B1 (fr)
SK (2) SK288019B6 (fr)
WO (1) WO2001047922A2 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
IL157029A0 (en) * 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
CA2480317A1 (fr) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n pour le traitement de troubles neurodegeneratifs
DE60331219D1 (de) * 2002-03-28 2010-03-25 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
JP2005526831A (ja) * 2002-04-09 2005-09-08 アステックス テクノロジー リミテッド 医薬化合物
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
EP1545515A1 (fr) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1599475A2 (fr) * 2003-03-06 2005-11-30 Eisai Co., Ltd. Inhibiteurs des jun-kinases (jnk)
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
EP1628975A2 (fr) 2003-05-16 2006-03-01 Eisai Co., Ltd. Inhibiteurs des jnk
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
NZ545326A (en) 2003-07-17 2009-12-24 Plexxikon Inc PPAR active compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1694686A1 (fr) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Inhibiteurs de kinase
TWI368507B (en) * 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1763524A1 (fr) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2589779A1 (fr) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
CA2589877A1 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP2354140A1 (fr) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines en tant qu'inhibiteurs de kinase
EP2251341A1 (fr) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US8076365B2 (en) * 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2621261C (fr) 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1963320A1 (fr) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Composes inhibant les pyrrolopyridine kinases
UA98449C2 (en) * 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20080083680A (ko) * 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
EP2865381A1 (fr) * 2006-05-18 2015-04-29 Pharmacyclics, Inc. Inhibiteurs de ITK pour le traitement des cancers des cellules sanguines
EP2125722A2 (fr) 2006-05-26 2009-12-02 AstraZeneca AB Indoles substitues par biaryl ou aryl-heteroaryl
WO2008014249A2 (fr) * 2006-07-24 2008-01-31 Sanofi-Aventis Préparation améliorée de composés d'azaindole
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US8513270B2 (en) * 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MY152948A (en) * 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
MX2010008198A (es) 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
EP2247595B1 (fr) * 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Inhibiteurs de kinase pyrrolopyrazine
WO2009106441A1 (fr) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de la pyrrolopyrazine kinase
WO2009106444A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
EP2250172B1 (fr) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Inhibiteurs de kinase pyrrolopyrazine
JP2011513488A (ja) * 2008-03-10 2011-04-28 サノフィ−アベンティス 眼関連障害の治療
JP5275371B2 (ja) * 2008-03-11 2013-08-28 インサイト・コーポレイション Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
WO2009132202A2 (fr) * 2008-04-24 2009-10-29 Incyte Corporation Composés macrocycliques et leur utilisation à titre d'inhibiteurs de kinase
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (fr) * 2008-10-21 2010-04-29 Syngenta Participations Ag Dérivés de diazaindole et leur emploi en tant que fongicides
WO2010085597A1 (fr) 2009-01-23 2010-07-29 Incyte Corporation Composés macrocycliques et leur utilisation en tant qu'inhibiteurs des kinases
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
LT2432472T (lt) * 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
MX2012000711A (es) * 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
US8816085B2 (en) 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
JP5946768B2 (ja) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
EP2338890A1 (fr) 2009-12-22 2011-06-29 Bayer CropScience AG Dérivés de 4,7-diazaindole et leur utilisation en tant que fongicides
CA2790070C (fr) * 2010-02-18 2018-03-06 Incyte Corporation Derives de cyclobutane et de methylcyclobutane comme inhibiteurs de janus kinases
WO2011109932A1 (fr) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Nouveau procédé pour la fabrication de 7-azaindoles 5-halogénés
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
KR20130083387A (ko) * 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 Syk 및 jak 억제제로서 피롤로피라진 유도체
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
EP2706852B1 (fr) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines en tant qu'inhibiteurs de syk
CN103619172A (zh) 2011-05-10 2014-03-05 默沙东公司 作为syk抑制剂的氨基嘧啶
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EP2741747A1 (fr) 2011-08-10 2014-06-18 Novartis Pharma AG Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2763974B1 (fr) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
JP6097770B2 (ja) * 2012-02-21 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ フロピリジン誘導体
WO2013173720A1 (fr) 2012-05-18 2013-11-21 Incyte Corporation Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
WO2013192128A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
EP2863916B1 (fr) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
KR101916443B1 (ko) 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
EP2884982B1 (fr) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
EP2900665B1 (fr) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
TW201444836A (zh) * 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
AR101528A1 (es) 2013-03-14 2016-12-28 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
MX2015012456A (es) 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10590111B2 (en) * 2014-12-11 2020-03-17 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017151409A1 (fr) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Méthodes de chimiothérapie
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
EP3694855A1 (fr) 2017-10-13 2020-08-19 Plexxikon Inc. Formes solides d'un composé pour la modulation de kinases
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021102258A1 (fr) 2019-11-22 2021-05-27 Incyte Corporation Polythérapie comprenant un inhibiteur d'alk2 et un inhibiteur de jak2
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (fr) * 1996-11-19 1998-05-28 Amgen Inc. Agents anti-inflammatoires a base de pyrrole condense a substitution aryle et heteroaryle
WO1998047889A1 (fr) * 1997-04-23 1998-10-29 Novartis Ag Derives de chromane
WO1999020624A1 (fr) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Inhibiteurs bicycliques d'une kinase

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) * 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
WO1995033748A1 (fr) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Antagonistes du recepteur de l'endotheline
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
WO1998047899A1 (fr) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires
DE69830409T2 (de) * 1997-08-05 2006-01-26 Pfizer Products Inc., Groton 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051595A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
AU3118399A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002510628A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
EP1071423A1 (fr) 1998-04-02 2001-01-31 Merck & Co., Inc. Antagonistes de la gonadoliberine
CA2326185A1 (fr) * 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
AU4183699A (en) 1998-05-12 1999-11-29 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1086950B1 (fr) 1998-05-26 2010-09-29 Chugai Seiyaku Kabushiki Kaisha Derives d'indole heterocycliques et derives de mono ou de di-azaindole
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
PL347138A1 (en) * 1998-09-18 2002-03-25 Basf Ag 4-aminopyrrolopyrimidines as kinase inhibitors
AU3126900A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Products Inc. Alpha-substitution of unprotected beta-amino ester compounds
EP1189889B1 (fr) 1999-06-04 2003-12-17 Elan Pharma International Limited Compositions et methodes permettant d'inhiber la mort cellulaire
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
EP1259236A4 (fr) 2000-02-25 2004-11-03 Merck & Co Inc Inhibiteurs de tyrosine-kinase
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
AU2001261189A1 (en) * 2000-05-03 2001-11-12 Tularik, Inc. Pyrazole antimicrobial agents
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (fr) * 1996-11-19 1998-05-28 Amgen Inc. Agents anti-inflammatoires a base de pyrrole condense a substitution aryle et heteroaryle
WO1998047889A1 (fr) * 1997-04-23 1998-10-29 Novartis Ag Derives de chromane
WO1999020624A1 (fr) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Inhibiteurs bicycliques d'une kinase

Also Published As

Publication number Publication date
WO2001047922A3 (fr) 2002-01-17
CA2395593C (fr) 2011-08-02
US7227020B2 (en) 2007-06-05
AP2002002516A0 (en) 2002-06-30
KR100755622B1 (ko) 2007-09-04
US20040198737A1 (en) 2004-10-07
NZ519121A (en) 2004-05-28
CZ20022207A3 (cs) 2002-11-13
EE05180B1 (et) 2009-06-15
EP1990343A3 (fr) 2008-12-10
HUP0203895A3 (en) 2004-09-28
MXPA02006338A (es) 2002-12-13
EA005212B1 (ru) 2004-12-30
EP1990343B1 (fr) 2012-04-04
HRP20020547A2 (hr) 2005-10-31
US6770643B2 (en) 2004-08-03
KR20020062663A (ko) 2002-07-26
HK1050191A1 (en) 2003-06-13
KR20070050103A (ko) 2007-05-14
NO330747B1 (no) 2011-07-04
WO2001047922A2 (fr) 2001-07-05
DZ3377A1 (fr) 2001-07-05
EP1990343A2 (fr) 2008-11-12
IL150388A0 (en) 2002-12-01
AU2209401A (en) 2001-07-09
BR0017038A (pt) 2003-01-07
CA2699568C (fr) 2013-03-12
AU777717B2 (en) 2004-10-28
SK287882B6 (sk) 2012-02-03
JP2012031181A (ja) 2012-02-16
CN1413213A (zh) 2003-04-23
BG106836A (bg) 2003-04-30
CZ301751B6 (cs) 2010-06-09
MA26857A1 (fr) 2004-12-20
EA200200707A1 (ru) 2003-02-27
AP2006003492A0 (en) 2006-02-28
EP1263759A2 (fr) 2002-12-11
EP1263759B1 (fr) 2010-09-08
HK1050191B (zh) 2011-04-29
CN1615873A (zh) 2005-05-18
NO20023032L (no) 2002-06-21
BG66176B1 (bg) 2011-11-30
JP5436507B2 (ja) 2014-03-05
BG66066B1 (bg) 2011-01-31
PL209572B1 (pl) 2011-09-30
CZ301750B6 (cs) 2010-06-09
PL355819A1 (en) 2004-05-17
SK288019B6 (sk) 2012-11-05
IL193615A0 (en) 2009-05-04
HRP20020547B1 (en) 2011-06-30
KR100910488B1 (ko) 2009-08-04
CA2395593A1 (fr) 2001-07-05
NO323766B1 (no) 2007-07-02
HUP0203895A2 (hu) 2003-02-28
IL150388A (en) 2010-11-30
NO20023032D0 (no) 2002-06-21
EE200200343A (et) 2003-06-16
US20040009983A1 (en) 2004-01-15
CN100379734C (zh) 2008-04-09
SK9012002A3 (en) 2003-04-01
OA12514A (en) 2006-05-29
CA2699568A1 (fr) 2001-07-05
CY1110951T1 (el) 2015-06-11
NO20066017L (no) 2002-06-21
AP1587A (en) 2006-03-02
BG110623A (bg) 2010-07-30

Similar Documents

Publication Publication Date Title
AP1917A (en) Azaindoles
DE60018571D1 (en) Hernienprothese
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50008011D1 (en) Thixotropierungsmittel
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
PL354600A1 (en) Naphthyridine derivatives
DE50002614D1 (en) Sigma-delta-modulator
DE50000137D1 (en) Spirofluorenopyrane
DE60011809D1 (en) Oxcarbazepinsuspension
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE60001313D1 (en) Imidazodiazepinderivate
DE60012950D1 (en) Polyacetalharzzusammensetzung
DE50009469D1 (en) Common-rail-injektor
HUP0200274A2 (en) Fitting
GB9912283D0 (en) Bio-power
DE50010757D1 (en) Stilbenaufheller
DE60026282D1 (en) Photovervielfacherröhre
DE50012999D1 (en) Stirnwandisolation
DE50008218D1 (en) Common-rail-injektor
EP1170018A4 (fr) Complexe lie par un ligand
DE60004080D1 (en) Centroidintegration